Navigation Links
EvaluatePharma USA, Inc. Welcomed Into Boston Biotech Community by Mayor Menino
Date:11/11/2010

EvaluatePharma USA, Inc. Welcomed Into Boston Biotech Community by Mayor Menino -- BOSTON, November 11, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Internet Technology, Multimedia & Internet, Web Site, Biotechnology, Medical Pharmaceuticals, Pharmaceuticals, Corporate Expansion Click to view news release full screen  

EvaluatePharma USA, Inc. Welcomed Into Boston Biotech Community by Mayor Menino

 

BOSTON, November 11, 2010 /PRNewswire/ -- EvaluatePharma USA, Inc. the online analysis service for the global biotechnology and pharmaceutical sector, was welcomed into Boston's biotech community today by Mayor Menino at the opening of their new office in Boston, the #1 life sciences cluster in the US.

Senior Vice President Debbie Paul said, "EvaluatePharma USA are very excited to be joining the Boston biotech community with the opening of our new office at Broad Street. Many of our clients are based in Boston and we will now be able to work more closely with the biotech community, supporting them with innovative products and services designed to help the commercialization of their products."

Commenting at the opening ceremony, Dr. Jonathan de Pass, CEO and Founder said "We are very grateful to Mayor Menino and the LifeTech programme for their help and support in the opening of this new office. EvaluatePharma is committed to developing new products and services that continue to support the biotech community such as the launch of our new service Partnering Opportunities. By registering their licensing assets with our Partnering Opportunities the biotech community can reach our global audience of business development and licensing professionals across the world's leading pharma companies."

EvaluatePharma's Partnering Opportunities is a new free service that allows potential partners to see the latest opportunities from the biotech community in their commercial context alongside EvaluatePharma's industry analysis, including product portfolios, company financials and reference deal terms.

Founded in 1996 by Dr. Jonathan de Pass, a former top-ranked Pharmaceutical analyst in the City of London, EvaluatePharma(R) provides proprietary insights into the commercial and financial prospects of the pharma and biotech industry and was the first company to provide reliable consensus forecasts of global drug sales. Analyses range from total market sales trends and therapeutic overviews to individual company financial performance and product progress.

EvaluatePharma's client base includes the top global pharma and biotech companies, the investment banking community and the leading global management consulting firms.

Notes to editors

About EvaluatePharma:

The research company EvaluatePharma was the first to supply reliable consensus forecasts of global drug sales and now provides standardised worldwide financial and forecast models with consensus product sales forecasts to 2016, data on R&D pipelines, licensing deals, patent risk and M&A activity. Launched in 2007, EvaluatePharma(R)Alpha offers a Net Present Value (NPV) valuation service quantifying market events and the impact on product, portfolio and company valuation including the daily online news service EP Vantage(R).

EvaluatePharma(R), EvaluatePharma(R)Alpha, and EP Vantage(R) are services of EvaluatePharma Ltd, headquartered in London, England. In North America, EvaluatePharma Ltd is represented by

EvaluatePharma USA, Inc. http://www.evaluatepharma.com Contact: Debbie Paul Senior Vice President, North America T: +1-866-806-1309 E: debbiep@evaluatepharma.com EvaluatePharma USA, Inc. 15 Broad Street, Suite 401 Boston, MA 02109 USA Andrew Beaven Marketing Director, EvaluatePharma Ltd T: +44(0)20-7539-1818 E: andrewb@evaluatepharma.com EvaluatePharma Ltd 11-29 Fashion Street London E1 6PX United Kingdom
'/>"/>

SOURCE EvaluatePharma Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SIGVARIS Provides Red Socks to Honor Efforts by Boston Red Sox Manager, Terry Francona, to Raise Awareness for DVT Prevention
2. PAREXEL International to Participate in the Lazard Capital Markets Healthcare Conference in New York and the Jefferies Healthcare Summit in Boston
3. Boston Scientific Agrees to Sell Neurovascular Business to Stryker
4. Boston Scientific Completes Acquisition of Asthmatx
5. Boston Scientific Announces CE Mark Approval for Expanded Indication of WallFlex® Biliary RX Stent
6. Boston Scientific Announces FDA Clearance and CE Mark Approval for Advanix™ Biliary Stents
7. Boston Scientific Announces Results for Third Quarter Ended September 30, 2010
8. Boston Scientific Announces Global Launch of Journey™ Guidewire
9. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
10. Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy
11. Boston Scientifics TAXUS® Element™ Stent Demonstrates Strong Outcomes in Diabetic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... , July 17, 2017  MedX Holdings, Inc., the ... testing, strengthening and rehabilitation equipment, today announced the national ... MedX is considered the gold standard for the treatment ... specialized medical strengthening equipment. ... with the physician or practice who prescribe the MedX ...
(Date:7/13/2017)... , July 13, 2017  Centurion Medical Products, a leader ... DisImpactor ® fecal impaction removal device for hospice patient care. ... Centurion ... Patient pain management and emotional ... Hospice can help alleviate patient pain while preventing unneeded emergency department ...
(Date:7/12/2017)... Lilly and Company (NYSE: LLY ) has entered ... patent litigation in the U.S. District Court for the Eastern ... ® (tadalafil) unit dose patent. This patent was previously ... the agreement, Cialis exclusivity is now expected to end at ... dose patent for Cialis is valid and infringed by companies ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Committed to eliminating clubfoot ... over 100,000 children in their treatment program. Clubfoot is a pervasive problem in ... treatment is limited or non-existent. Without intervention, these children are destined to grow ...
(Date:7/24/2017)... Falls Church, VA (PRWEB) , ... July 24, ... ... is figuring out how to change manufacturers future. , The agency is hammering ... Century Cures Act, one of the farthest-ranging laws ever to affect FDA-regulated firms. ...
(Date:7/24/2017)... ... ... “The Perfect Gift”: a customizable and interactive Bible study guide for children. “The Perfect Gift” ... She has always accepted Christ as her Savior, yet never studied His word, surrendered ... when she wrote this book to her children, so they would know the importance of ...
(Date:7/24/2017)... ... July 24, 2017 , ... “Journey to the Light: ... novel that details a young woman’s path to finding herself. “Journey to the ... of published author, Jamie Grayson, an experienced writer of newsletters, manuals, and articles, who ...
(Date:7/23/2017)... ... July 23, 2017 , ... ... of education and training standards for healthcare treatment providers, offers healthcare professionals ... the iaedp™ Core Curriculum. , Presented as either online or as a ...
Breaking Medicine News(10 mins):